Protocol Review and Monitoring at Roswell Park Cancer Institute (RPCI) is under the direct supervision of Dr Alex Adjei, Associate Director for Clinical Research. Components include the Scientific Review Committee (SRC), the Response Review Committee (RRC), the Clinical Research Management System (CRMS) and the new Clinical Research Feasibility and Prioritization Committee (CRFPC). The SRC provides oversight and assures the maintenance of high quality institutional clinical research. All research studies conducted at RPCI are reviewed by the SRC prior to submission to the IRB. The scope of the SRC responsibilities includes review and approval of new and ongoing clinical research studies, review and approval of study amendments and review and approval of the outcome of the analysis of non-accruing and slow accruing studies. The SRC reviews new studies to ensure that scientific content and study design are appropriate and that statistical oversight and collaboration is in place. The review of non-accruing and slow accruing studies occurs twice annually. The SRC provides a forum where the utilization of RPCI resources and the prioritization of clinical research studies are discussed. The Response Review Committee is charged with monitoring radiological response assessment and reporting the outcome of the review to the Scientific Review Committee and the Data and Safety Monitoring Board. Ellis Levine, MD, chairs the Response Review Committee and Alan Li twin, MD, provides the radiological review conducted by the Response Review Committee. Under the leadership and supervision of Dr Alex Adjei, Joyce Yasko, PhD oversees the function of the SRC including the development of prompt SRC communication of the outcome of the SRC review with the Principal Investigators and the review of slow or non accruing research studies. Julie Haney BS, CRS Director, Study Submission and Regulatory Affairs provides the administrative support for the role, responsibilities and outcomes of the SRC. Jennifer Cartonia provides critical secretarial support to the SRC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-36
Application #
8375970
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
36
Fiscal Year
2012
Total Cost
$190,802
Indirect Cost
$75,530
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Wintrob, Zachary A P; Hammel, Jeffrey P; Nimako, George K et al. (2017) Insulin use, hormone receptor status and hematopoietic cytokines? circulation in women with diabetes mellitus and breast cancer. Data Brief 11:382-390
Murphy, Maureen E; Liu, Song; Yao, Song et al. (2017) A functionally significant SNP in TP53 and breast cancer risk in African-American women. NPJ Breast Cancer 3:5
Liu, Song; Kumari, Sangeeta; Hu, Qiang et al. (2017) A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. Elife 6:
Espinal, Allyson C; Buas, Matthew F; Wang, Dan et al. (2017) FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women? Breast Cancer Res Treat 166:559-568
Danaher, Patrick; Warren, Sarah; Dennis, Lucas et al. (2017) Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer 5:18
Oakley, Emily; Bellnier, David A; Hutson, Alan et al. (2017) Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer. Lasers Surg Med 49:599-608
Gage-Bouchard, Elizabeth A (2017) Social support, flexible resources, and health care navigation. Soc Sci Med 190:111-118
Moore, Kathleen N; Tritchler, David; Kaufman, Kenneth M et al. (2017) Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:396-401
Szender, J Brian; Papanicolau-Sengos, Antonios; Eng, Kevin H et al. (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420-425
Ho, Christine M; McCarthy, Philip L; Wallace, Paul K et al. (2017) Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Adv 1:1056-1066

Showing the most recent 10 out of 1391 publications